International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
Consensus StatementСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kittai Adam S, Marchetti Monia, Al-Sawaf Othman, Benjamini Ohad, Danilov Alexey V, Davids Matthew S, Eichhorst Barbara, Eyre Toby A, Frustaci Anna Maria, Hallek Michael, Hampel Paul J, Herishanu Yair, Hicks Rodney J, Kater Arnon P, King Rebecca L, Martin-Subero Jose I, Owen Carolyn, Parry Erin, Ponzoni Maurilio, Rossi Davide, Siddiqi Tanya, Stilgenbauer Stephan, Tam Constantine S, Hacken Elisa Ten, Thompson Philip A, Wierda William, Gaidano Gianluca, Woyach Jennifer A, Ghia Paolo
Аннотация
Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Despite novel therapeutics developed in CLL, RT is associated with poor outcomes. In light of recent progress regarding the diagnostic procedures and therapeutic concepts of RT, an international group of experts, under the coordination of the European Research Initiative on CLL, has developed consensus recommendations for clinical procedures and future research on this disease. Patients with RT typically present with a rapid clinical decline, worsening B-symptoms, elevated lactate dehydrogenase, and/or rapidly enlarging lymphadenopathy. Workup should include a positron emission tomography-computed tomography scan for patients with suspected RT. An excisional biopsy should be taken from an accessible lesion, preferably with the highest fluorodeoxyglucose avidity, and analyzed for the presence of aggressive lymphoma. The molecular relationship to the original CLL clone(s) should be defined. Because no effective standard treatment for RT exists, patients should be treated in a clinical trial. Response of both RT and CLL should be assessed at an early time point, and survival end points should be prioritized in trial design. We hope that these recommendations can help to harmonize clinical and translational research and improve outcomes for patients with RT.